Revised: 31 May 2019
Medicines
Medsafe Product Detail | ![]() ![]() | |
---|---|---|
File ref: TT50-9713 |
Trade Name | Dose Form | Strength | Identifier |
VIMIZIM | Concentrate for injection | 1 mg/mL | |
Sponsor | Application date | Registration situation | Classification |
Pharmacy Retailing (NZ) Ltd t/a Healthcare Logistics P O Box 62027 Sylvia Park AUCKLAND 1644 | 19/2/2015 | Consent given Approval date: 20/8/2015 Notification date: 28/6/2016 | Prescription |
Composition
Component | Ingredient | Manufacturer |
concentrate for injection | Active | |
Elosulfase alfa 1 mg/mL | BioMarin International Ltd. Shanbally Ringaskiddy Co. Cork Ireland | |
BioMarin Pharmaceutical Inc 46 Galli Drive Novato California 94949 United States of America | ||
Excipient | ||
Arginine hydrochloride | ||
Monobasic sodium phosphate monohydrate | ||
Polysorbate 20 | ||
Sodium acetate trihydrate | ||
Sorbitol | ||
Water for injection |
Production
Manufacturing step | Manufacturer |
Finished Product Testing | BioMarin International Ltd. Shanbally Ringaskiddy Co. Cork Ireland |
BioMarin Pharmaceutical Inc 300 Bel Marin Keys Novato CA 94949 United States of America | |
Vetter Pharma-Fertigung GmbH & Co KG Eisenbahnstrasse 2-4 Langenargen D-88085 Germany | |
Vetter Pharma-Fertigung GmbH & Co KG Helmut-Vetter-Str. 10 Ravensburg Baden Wurttemberg 88213 Germany | |
Vetter Pharma-Fertigung GmbH & Co KG Mooswiesen 2 Ravensburg D-88214 Germany | |
Vetter Pharma-Fertigung GmbH & Co KG Schuetzenstrasse 87, 99-101 Ravensburg D-88212 Germany | |
Manufacture of Final Dose Form | Vetter Pharma-Fertigung GmbH & Co KG Eisenbahnstrasse 2-4 Langenargen D-88085 Germany |
Vetter Pharma-Fertigung GmbH & Co KG Mooswiesen 2 Ravensburg D-88214 Germany | |
Secondary Packaging | AndersonBrecon (UK) Limited Wye Valley Business Park Brecon Road, Hay-on-Wye Hereford HR3 5PG United Kingdom |
AndersonBrecon Inc 4545 Assembly Drive Rockford Illinois 61109 United States of America | |
BioMarin International Ltd. Shanbally Ringaskiddy Co. Cork Ireland | |
NZ Site of Product Release | Pharmacy Retailing (NZ) Ltd t/a Healthcare Logistics 58 Richard Pearse Drive Airport Oaks Mangere AUCKLAND 2022 |
Packaging
Package | Contents | Shelf Life |
Vial, glass, | 5 mL | 36 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze) protect from light |
Indications
Treatment of mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome) in children and adults of all ages.
Latest Regulatory Activity
Application Date | Application Type | Change(s) | Status | Payment Date | Priority |
27/6/2022 | Changed Medicine Notification | Active ingredient method of manufacture - Grade 2 | Granted 11/7/2022 | 7/7/2022 | |
19/2/2015 | New Higher-risk Medicine Application | Abridged new higher-risk medicine containing one or more new active substance | Granted 20/8/2015 | 4/3/2015 | Y |